Mostrar el registro sencillo del ítem

dc.contributor.authorBekri, Selmaes_ES
dc.contributor.authorBourdely, Pierrees_ES
dc.contributor.authorLuci, Carmeloes_ES
dc.contributor.authorDereuddre-Bosquet, Nathaliees_ES
dc.contributor.authorSu, Bines_ES
dc.contributor.authorMartinon, Fréderices_ES
dc.contributor.authorBraud, Véronique M.es_ES
dc.contributor.authorLuque Fernández, Irene es_ES
dc.contributor.authorMateo Alarcón, Pedro Luis es_ES
dc.contributor.authorCrespillo, Saraes_ES
dc.contributor.authorConejero Lara, Francisco es_ES
dc.contributor.authorMoog, Christianees_ES
dc.contributor.authorGrand, Roger Lees_ES
dc.contributor.authorAnjuère, Fabiennees
dc.date.accessioned2017-03-10T12:21:32Z
dc.date.available2017-03-10T12:21:32Z
dc.date.issued2017
dc.identifier.citationBekri, S.; et al. Sublingual Priming with a HIV gp41-Based Subunit Vaccine Elicits Mucosal Antibodies and Persistent B Memory Responses in Non-Human Primates. Frontiers in Immunology, 8: 63 (2017). [http://hdl.handle.net/10481/45202]es_ES
dc.identifier.issn1664-3224
dc.identifier.urihttp://hdl.handle.net/10481/45202
dc.description.abstractPersistent B cell responses in mucosal tissues are crucial to control infection against sexually transmitted pathogens like human immunodeficiency virus 1 (HIV-1). The genital tract is a major site of infection by HIV. Sublingual (SL) immunization in mice was previously shown to generate HIV-specific B cell immunity that disseminates to the genital tract. We report here the immunogenicity in female cynomolgus macaques of a SL vaccine based on a modified gp41 polypeptide coupled to the cholera toxin B subunit designed to expose hidden epitopes and to improve mucosal retention. Combined SL/intramuscular (IM) immunization with such mucoadhesive gp41-based vaccine elicited mucosal HIV-specific IgG and IgA antibodies more efficiently than IM immunization alone. This strategy increased the number and duration of gp41-specific IgA secreting cells. Importantly, combined immunization improved the generation of functional antibodies 3 months after vaccination as detected in HIV-neutralizing assays. Therefore, SL immunization represents a promising vaccine strategy to block HIV-1 transmission.en_EN
dc.description.sponsorshipThese studies were supported by Institut National de la Santé et de la Recherche Médicale (INSERM, France) by Centre National de Recherche Scientifique (CNRS, France), by the Agence Nationale de Recherche sur le SIDA (France), the SIDACTION (France), by the Euroneut-41 European Consortium (FP7 program), by the National Research Agency (ANR) through the “Investments for the Future” LABEX SIGNALIFE (ANR-11-LABX-0028-01) and the “Investments for the future” under Grant ANR-11-INBS-0008 funding the Infectious Disease Models and Innovative Therapies (IDMIT, Fontenay-aux-Roses, France) infrastructure and ANR-10-EQPX-02-01 funding the FlowCyTech facility.en_EN
dc.language.isoeng
dc.publisherFrontiers Mediaes_ES
dc.relationnfo:eu-repo/grantAgreement/EC/FP7/201038
dc.rightsCreative Commons Attribution-NonCommercial-NoDerivs 3.0 License
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/
dc.subjectSublingual immunizationen_EN
dc.subjectMucosal antibodiesen_EN
dc.subjectB Memory responseen_EN
dc.subjectNeutralizationen_EN
dc.subjectHIVen_EN
dc.subjectTrimeric gp41en_EN
dc.subjectCholera toxin B subuniten_EN
dc.titleSublingual Priming with a HIV gp41-Based Subunit Vaccine Elicits Mucosal Antibodies and Persistent B Memory Responses in Non-Human Primatesen_EN
dc.typejournal article
dc.rights.accessRightsopen access
dc.identifier.doi10.3389/fimmu.2017.00063


Ficheros en el ítem

[PDF]

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License
Excepto si se señala otra cosa, la licencia del ítem se describe como Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License